Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) has been given an average recommendation of “Buy” by the seven analysts that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $15.40.
A number of equities research analysts have recently weighed in on FOMX shares. Zacks Investment Research upgraded Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 22nd. Cowen set a $30.00 price target on Foamix Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, September 23rd. Finally, HC Wainwright restated a “buy” rating and set a $11.00 price target (up previously from $10.00) on shares of Foamix Pharmaceuticals in a research note on Monday, October 21st.
FOMX opened at $2.79 on Tuesday. The business’s 50-day moving average is $3.31 and its two-hundred day moving average is $2.90. Foamix Pharmaceuticals has a 1 year low of $1.97 and a 1 year high of $4.48. The company has a current ratio of 5.72, a quick ratio of 5.72 and a debt-to-equity ratio of 0.24.
Several hedge funds have recently modified their holdings of the company. Royal Bank of Canada grew its stake in shares of Foamix Pharmaceuticals by 76.5% during the second quarter. Royal Bank of Canada now owns 13,694 shares of the specialty pharmaceutical company’s stock worth $33,000 after acquiring an additional 5,937 shares during the last quarter. grace capital grew its stake in shares of Foamix Pharmaceuticals by 86.9% during the second quarter. grace capital now owns 20,000 shares of the specialty pharmaceutical company’s stock worth $48,000 after acquiring an additional 9,300 shares during the last quarter. Worth Venture Partners LLC grew its stake in shares of Foamix Pharmaceuticals by 75.0% during the second quarter. Worth Venture Partners LLC now owns 23,627 shares of the specialty pharmaceutical company’s stock worth $56,000 after acquiring an additional 10,127 shares during the last quarter. Delek Group Ltd. grew its stake in shares of Foamix Pharmaceuticals by 23.2% during the second quarter. Delek Group Ltd. now owns 62,437 shares of the specialty pharmaceutical company’s stock worth $145,000 after acquiring an additional 11,741 shares during the last quarter. Finally, Stifel Financial Corp purchased a new stake in shares of Foamix Pharmaceuticals during the third quarter worth about $54,000. Institutional investors and hedge funds own 47.29% of the company’s stock.
Foamix Pharmaceuticals Company Profile
Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea.
See Also: Overbought
Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.